Telix Pharmaceuticals logo

Telix Pharmaceuticals Share Price (NASDAQ: TLX)

$12.36

0.27

(2.23%)

Live

Last updated on

Check the interactive Telix Pharmaceuticals Stock chart to analyse performance

Telix Pharmaceuticals stock performance

as on August 23, 2025 at 12:34 AM IST

  • Today's Low:$12.14
    Today's High:$12.47

    Day's Volatility :2.65%

  • 52 Weeks Low:$10.50
    52 Weeks High:$30.36

    52 Weeks Volatility :65.42%

Telix Pharmaceuticals Stock Returns

PeriodTelix Pharmaceuticals LtdIndex (Russel 2000)
3 Months
-27.26%
0.0%
6 Months
-38.08%
0.0%
1 Year
-20.3%
0.0%
3 Years
-20.3%
-7.7%

Telix Pharmaceuticals Ltd Key Stats

Check Telix Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$12.09
Open
$11.6
Today's High
$12.5
Today's Low
$12.14
Market Capitalization
$5.2B
Today's Volume
$309.5K
52 Week High
$30.36
52 Week Low
$10.5
Revenue TTM
$645.7M
EBITDA
$73.1M
Earnings Per Share (EPS)
$0.09
PE Ratio
173.44
Profit Margin
7.62%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
20.49%

Stock Returns calculator for Telix Pharmaceuticals Stock including INR - Dollar returns

The Telix Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Telix Pharmaceuticals investment value today

Current value as on today

₹85,865

Returns

₹14,135

(-14.13%)

Returns from Telix Pharmaceuticals Stock

₹18,416 (-18.42%)

Dollar Returns*

₹4,281 (+4.28%)

Indian investors sentiment towards Telix Pharmaceuticals Stock

245%

Period: Jul 22, 2025 to Aug 21, 2025. Change in 30 Days versus previous period

Search interest for Telix Pharmaceuticals Stock from India on INDmoney has increased by 245% in the last 30 days, reflecting an upward trend in search activity.

Analyst Recommendation on Telix Pharmaceuticals Stock

Rating
Trend

Telix Pharmaceuticals Share Price Target

What analysts predicted

Upside of 63.32%

Target:

$20.19

Current:

$12.36

Telix Pharmaceuticals share price target is $20.19, a slight Upside of 63.32% compared to current price of $12.36 as per analysts' prediction.

Telix Pharmaceuticals Stock Insights

  • Price Movement

    In the last 7 days, TLX stock has moved up by 4.6%

Telix Pharmaceuticals Ltd Financials

Revenue
Profit
Cash Flow
Annually
Quarterly
FY19
FY20
FY21
FY22
FY23
FY24
FY24Y/Y Change
Revenue
$495.2M
↑ 55.85%
Net Income
$31.6M
↑ 857.95%
Net Profit Margin
6.37%
↑ 5.33%

Telix Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Telix Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Telix Pharmaceuticals Ltd Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Telix Pharmaceuticals Ltd logo
-17.18%
-38.08%
-20.3%
-20.3%
-20.3%
Regeneron Pharmaceuticals, Inc. logo
4.5%
-14.59%
-49.64%
-0.73%
0.56%
Beone Medicines Ltd logo
6.48%
22.93%
60.47%
81.44%
32.24%
Vertex Pharmaceuticals Incorporated logo
-16.69%
-17.94%
-17.2%
38.81%
48.58%
Alnylam Pharmaceuticals, Inc. logo
43.34%
86.27%
68.31%
115.22%
254.29%

About Telix Pharmaceuticals Ltd

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing TLX250-CDx, a positron emission tomography (PET) diagnostic imaging agent for the characterization of renal masses as clear cell renal cell carcinoma; TLX101-CDx, a PET diagnostic agent to image cancerous lesions in the brain; and TLX66-CDx, a cluster of differentiation 66 imaging agent for osteomyelitis (bone infection). It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Organization
Telix Pharmaceuticals
Employees
0
CEO
Mr. Richard Valeix M.B.A.
Industry
Miscellaneous

Key Management of Telix Pharmaceuticals Ltd

NameTitle
Mr. Darren Smith B.Bus., FCPA, M.B.A.
Group Chief Financial Officer
Mr. Darren Patti Pharm.D.
Group Chief Operating Officer
Dr. Andreas Kluge M.D., Ph.D.
Chief Medical Advisor
Dr. David N. Cade M.B.A., M.D., MBBS
Group Chief Medical Officer
Mr. Richard Valeix M.B.A.
Chief Executive Officer of Telix Therapeutics
Dr. Paul Schaffer
Chief Technology Officer
Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab)
Chief Scientist
Mr. Craig Ulrick
Chief Information Officer
Ms. Kyahn Williamson B.A.
Senior Vice President of Corporate Communications & Investor Relations
Ms. Lena Moran-Adams L.L.B.
Group General Counsel

Important FAQs about investing in TLX Stock from India :

What is Telix Pharmaceuticals share price today?

Telix Pharmaceuticals share price today is $12.36 as on . Telix Pharmaceuticals share today touched a day high of $12.47 and a low of $12.14.

What is the 52 week high and 52 week low for Telix Pharmaceuticals share?

Telix Pharmaceuticals share touched a 52 week high of $30.36 and a 52 week low of $10.50. Telix Pharmaceuticals stock price today i.e. is trending at $12.36, lower by 59.29% versus the 52 week high.

How to invest in Telix Pharmaceuticals Stock (TLX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Telix Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Telix Pharmaceuticals Shares that will get you 0.1214 shares as per Telix Pharmaceuticals share price of $12.36 per share as on August 23, 2025 at 12:34 AM IST.

What is the minimum amount required to buy Telix Pharmaceuticals Stock (TLX) from India?

Indian investors can start investing in Telix Pharmaceuticals (TLX) shares with as little as ₹87.521 or $1 (as of August 22, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Telix Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 22, 2025). Based on Telix Pharmaceuticals share’s latest price of $12.36 as on August 23, 2025 at 12:34 AM IST, you will get 0.8091 shares of Telix Pharmaceuticals. Learn more about fractional shares .

What are the returns that Telix Pharmaceuticals has given to Indian investors in the last 5 years?

Telix Pharmaceuticals stock has given -20.3% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?